STAT+: OpenEvidence raises $250 million, doubling its valuation
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding.<\/p>\n
The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company\u2019s primary business model is advertising shown to clinicians.\u00a0<\/p>\n
Founded in 2022, OpenEvidence is one of the most prominent and best-funded companies from a wave of health artificial intelligence companies that emerged since the widespread availability of large language models. Reflecting on the eye-popping fundraising for health AI, a Silicon Valley Bank report<\/a> released earlier in January raised an eyebrow at the ability of companies like OpenEvidence to deliver on their stratospheric valuations with advertising and software-as-a-service business models. \u201cIt won\u2019t be a surprise to see them tap the value of the data they\u2019re already collecting\u201d to offer more services to pharma or other customers, the authors wrote.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n